Bryn Mawr Capital Management LLC Has $1.25 Million Holdings in Novartis AG (NYSE:NVS)

Bryn Mawr Capital Management LLC increased its position in shares of Novartis AG (NYSE:NVS) by 0.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,884 shares of the company’s stock after acquiring an additional 100 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Novartis were worth $1,254,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Legacy Investment Solutions LLC purchased a new position in Novartis during the third quarter valued at approximately $28,000. Human Investing LLC bought a new stake in Novartis in the fourth quarter worth approximately $25,000. Union Bancaire Privee UBP SA bought a new stake in Novartis in the fourth quarter worth approximately $27,000. Fortitude Family Office LLC grew its position in Novartis by 503.8% in the third quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after acquiring an additional 267 shares in the last quarter. Finally, Kestra Investment Management LLC bought a new stake in Novartis in the fourth quarter worth approximately $47,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on NVS. Deutsche Bank Aktiengesellschaft raised shares of Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. UBS Group reissued a “neutral” rating on shares of Novartis in a research report on Thursday, February 13th. Barclays reissued an “underweight” rating on shares of Novartis in a research report on Monday, February 3rd. HSBC downgraded shares of Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Finally, Morgan Stanley initiated coverage on shares of Novartis in a report on Wednesday, February 12th. They set an “underweight” rating for the company. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Novartis currently has a consensus rating of “Hold” and an average target price of $123.38.

Novartis Price Performance

NYSE NVS opened at $107.95 on Thursday. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $102.12 and a 200 day simple moving average of $108.08. The company has a market cap of $220.64 billion, a P/E ratio of 18.36, a P/E/G ratio of 1.70 and a beta of 0.58. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92.

Novartis (NYSE:NVS) last released its earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, beating the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, sell-side analysts predict that Novartis AG will post 8.45 EPS for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.